S12 Ep8: How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD
In today’s episode, we had the pleasure of speaking with David Gerber, MD, a professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center, a member of its Division of Hematology/Oncology, and co-director of Education and Training for the Harold C. Simmons Comprehensive Cancer Center in Dallas.
In our exclusive interview, Dr Gerber discussed the evolving role of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), focusing on findings from key clinical trials. He highlighted results from the phase 3 TROPION-Lung01 trial…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.